Composition, medicine and preparation method for treating cow mastitis

Abstract

The present invention relates to the technical field of veterinary medicine, and specifically discloses a composition for treating cow mastitis and a preparation method thereof. The composition includes: 0.5 part-2 parts of a composite sodium chlorite effervescent tablet, 1.2 parts-1.5 parts of puerarin, 1.8 parts-2.0 parts of a chitosan-derived quaternary ammonium salt, 1 part-5 parts of modified nano zinc oxide, 2 parts-6 parts of magnesium-aluminum hydrotalcite, 1.6 parts-3 parts of an antibacterial agent, 5 parts-10 parts of a film former, 2 parts-4 parts of a plasticizer, 3 parts-7 parts of a surfactant, 1 part-2 parts of a thickener, and 550 parts-650 parts of distilled water. The composition provided by the present invention can fundamentally treat and prevent cow mastitis under the synergistic effect of each component, with a cure rate of more than 90%, and will not cause drug residues, thereby avoiding the generation of drug residues and bacterial resistance problems in cow's milk. The composition is suitable for promotion in animal husbandry and has broad application prospects.

Description

Technical Field

[0001] The present invention relates to the technical field of veterinary medicines, and in particular to a composition, a medicine and a preparation method for treating cow cephalic inflammation. Background Art

[0002] Mastitis is the most common mammary gland disease in dairy cows. It refers to inflammatory changes in the mammary gland caused by viral or bacterial invasion. It is common in high-yielding cows during the early stages of lactation or during periods of high milk production. It is a common and frequently occurring disease in dairy cows. Mastitis not only reduces milk production but also reduces milk quality, shortens the lifespan of dairy cows, and increases the cost of replacement cows, resulting in significant economic losses for the dairy industry. Therefore, strengthening the prevention and treatment of mastitis is of vital importance to ensure the healthy, efficient, and sustainable development of the dairy industry.

[0003] Currently, there are many types of dairy cow teat dips on the market. Commonly used clinical dips include iodine preparations, chlorine dioxide, and peroxides. However, the active ingredient content in these dips is difficult to control, and dosage deviations can irritate the cow's skin, leading to worsening of the condition. Furthermore, commonly used iodine preparations are prone to residue in milk, resulting in excessive iodine levels in milk, which in turn affects milk quality and food safety. Furthermore, these chemical dips can cause a continuous increase in drug-resistant strains, creating certain difficulties in the prevention and treatment of dairy cow mastitis. Traditional Chinese medicines are derived from animals, plants, or minerals, are less likely to cause pathogens to develop drug resistance, are rapidly metabolized in the body, are highly effective, have low toxicity, and leave no residue, do not affect milk consumption during treatment, and have the dual effects of both medicine and nutrition. However, existing traditional Chinese medicine preparations for treating dairy cow mastitis often suffer from problems such as excessive dosage, unstable results, slow onset of action, and long treatment courses, which have become bottlenecks restricting their industrialization. Summary of the Invention

[0004] In view of the problems that existing preparations for treating cow mastitis often have, such as strong irritation to cow skin, large addition dosage, and long treatment course, the present invention provides a composition, medicine and preparation method for treating cow mastitis.

[0005] In order to solve the above technical problems, the technical solution provided by the present invention is:

[0006] A composition for treating cow mastitis comprises the following raw material components in parts by weight: 0.5-2 parts of a composite sodium chlorite effervescent tablet, 1.2-1.5 parts of puerarin, 1.8-2.0 parts of a chitosan-derived quaternary ammonium salt, 1-5 parts of modified nano zinc oxide, 2-6 parts of magnesium-aluminum hydrotalcite, 1.6-3 parts of an antibacterial agent, 5-10 parts of a film-forming agent, 2-4 parts of a plasticizer, 3-7 parts of a surfactant, 1-2 parts of a thickener, and 550-650 parts of distilled water.

[0007] Compared with the prior art, the composition for treating cow mastitis provided by the present invention uses composite sodium chlorite effervescent tablets, modified nano zinc oxide and chitosan-derived quaternary ammonium salt as main bactericidal components. The modified nano zinc oxide and chitosan-derived quaternary ammonium salt can enhance the activity of sodium chlorite, thereby reducing the amount of composite sodium chlorite effervescent tablets while improving the bactericidal effect. Moreover, the modified nano zinc oxide can be evenly dispersed in the film-forming agent to promote rapid film formation of the drug. In addition, the modified nano zinc oxide and the chitosan-derived quaternary ammonium salt are connected by chemical bonding, which can adjust the pore structure and hydrophilic-hydrophobic balance of the film, control the swelling of the film, thereby improving the stability and mechanical strength of the film, making the film soft and buffering, and not easy to break, thereby being more It can better protect the diseased parts and promote wound healing; magnesium aluminum hydrotalcite can efficiently carry bactericidal active ingredients, prolong and stabilize the bactericidal effect of chlorine dioxide, and at the same time, it can protect the bactericidal active ingredients and prevent the active ingredients from being destroyed by harsh biological, chemical or physical environments, greatly improving the stability of the active ingredients. In addition, magnesium aluminum hydrotalcite and modified nano zinc oxide can work together to adsorb on the bacterial membrane of bacteria through electrostatic action, destroy the membrane function of bacteria, and prevent biomass from entering and flowing out, thereby effectively improving the bactericidal rate; adding puerarin as a traditional Chinese medicine component can enhance the immunity of dairy cows, relieve the discomfort of dairy cows during illness, promote lactation and repair damaged tissues, and minimize the occurrence of a significant decrease in milk production due to illness.

[0008] The composition provided by the present invention can fundamentally treat and prevent cow mastitis under the synergistic effect of various components, with a cure rate of more than 90%, and will not cause drug residues, avoiding the generation of drug residues and bacterial resistance problems in cow milk, and has high practical value and promotion value.

[0009] Preferably, the composite sodium chlorite effervescent tablet comprises the following raw material components in parts by mass: 3.6-5.0 parts of sodium chlorite, 8.2-8.6 parts of tartaric acid, 0.7-1.3 parts of sodium tetraborate, 0.7-1.3 parts of sodium lauryl sulfate, 2.4-2.7 parts of sodium bicarbonate, 0.6-0.9 parts of methylcellulose, 1.9-2.3 parts of polyethylene glycol and 1.7-1.9 parts of a coating stabilizer.

[0010] More preferably, the coating stabilizer is a mixture of magnesium sulfate and nano-silicon dioxide in a mass ratio of 2-2.4:1.

[0011] Illustratively, the above raw materials are mixed evenly and then tableted using a conventional tableting method in the art to produce a composite sodium chlorite effervescent tablet.

[0012] The preferred composite sodium chlorite effervescent tablet has strong solubility, fast activation and high stability, and can quickly exert a bactericidal effect after being dissolved in water.

[0013] Preferably, the preparation method of the modified nano zinc oxide comprises the following steps:

[0014] S1, crushing the rambutan peel, adding it to an ethanol solution, extracting it at 30°C-50°C for 1 hour-2 hours, separating the solid and the liquid, repeating the extraction 2-3 times, and combining the extracts to obtain a rambutan extract;

[0015] S2, uniformly mixing the zinc nitrate solution and the rambutan extract, hydrothermally reacting at 60-70° C. for 1 h-1.5 h, separating the solid and the liquid, and calcining the obtained solid at 450-550° C. for 15-20 min to obtain modified zinc oxide nanoparticles.

[0016] Preferably, in combination with the above, the mass-to-volume ratio of the rambutan peel to the ethanol solution is 1:50-60, wherein the unit of mass is gram and the unit of volume is milliliter.

[0017] Preferably, in combination with the above, the mass concentration of the ethanol solution is 90%-95%.

[0018] Preferably, in combination with the above, the concentration of the zinc nitrate solution is 0.2 mol / L-0.5 mol / L, and the volume ratio of the zinc nitrate solution to the rambutan extract is 1:4-8.

[0019] By using rambutan extract as raw material and solvent to prepare nano zinc oxide, the dispersibility of nano zinc oxide in the film-forming agent can be improved, and the activity of nano zinc oxide can also be significantly improved, so that the bactericidal performance of nano zinc oxide under photocatalysis is significantly improved. It can also promote film formation in the drug bath under light conditions, shorten the film formation time, and quickly protect existing damaged and swollen areas; in addition, the modified nano zinc oxide can also serve as an activity stimulator of sodium chlorite, thereby improving the bactericidal activity of sodium chlorite.

[0020] Preferably, the preparation method of the chitosan-derived quaternary ammonium salt comprises the following steps:

[0021] Dissolve chitosan in isopropanol solution, adjust the pH to 8-9, then add 2,3-epoxypropyltrimethylammonium chloride aqueous solution, react at 60°C-90°C for 6h-10h, and dry to obtain chitosan-derived quaternary ammonium salt.

[0022] Optionally, the mass concentration of the isopropanol solution is 5%-6%, and the volume-to-mass ratio of the isopropanol solution to chitosan is 100:2.5-3, wherein the unit of volume is milliliter and the unit of mass is gram.

[0023] Optionally, the mass concentration of the 2,3-epoxypropyltrimethylammonium chloride aqueous solution is 70%-80%, and the volume-to-mass ratio of the 2,3-epoxypropyltrimethylammonium chloride aqueous solution to chitosan is 20-25:2.5-3, wherein the unit of volume is milliliter and the unit of mass is gram.

[0024] The preferred chitosan-derived quaternary ammonium salt has excellent bactericidal activity, can reduce the amount of compound sodium chlorite effervescent tablets added, and will not produce drug resistance, which is beneficial to ensuring the safety of milk products.

[0025] Exemplarily, the preparation method of the magnesium-aluminum hydrotalcite comprises the following steps:

[0026] 0.25 mol / L aluminum nitrate solution and 0.75 mol / L magnesium nitrate solution were mixed uniformly in a volume ratio of 0.8:1. 50 mL of 0.35 mol / L sodium hydroxide solution and 100 mL of 0.5 mol / L sodium nitrate solution were added dropwise to 500 mL of the mixed solution at 70°C. The pH of the system was always controlled at 10.5-11.0 during the addition. After the addition was completed, the mixture was reacted for 5 h, centrifuged, washed, and dried to obtain magnesium-aluminum hydrotalcite.

[0027] The magnesium-aluminum hydrotalcite prepared by the above method has a large specific surface area, can effectively carry active components, and protect the active components from being damaged by the environment. In addition, the magnesium-aluminum hydrotalcite and water can generate active oxygen under light, and also have a certain bactericidal effect.

[0028] Preferably, the antibacterial agent is a mixture of Galla chinensis extract, Schisandra chinensis extract and Coptis chinensis extract in a mass ratio of 1-1.2:1.-1.2:0.5-0.8.

[0029] Gallnut, Schisandra chinensis and Coptis chinensis work together to fully exert their analgesic, anti-inflammatory and antibacterial effects, and effectively repair damaged skin and mucous membranes, alleviating the discomfort of dairy cows during illness.

[0030] Preferably, the film-forming agent is a mixture of sodium alginate and chitosan quaternary ammonium salt microspheres in a mass ratio of 1.8-2.5:1.

[0031] Adding chitosan quaternary ammonium salt microspheres to the film-forming agent in synergy with magnesium aluminum hydrotalcite can effectively carry bactericidal active components, prolong and stabilize the bactericidal effect of chlorine dioxide, and greatly improve the stability of the active ingredients; in addition, chitosan quaternary ammonium salt microspheres can also inhibit the disintegration of compound sodium chlorite effervescent tablets, prolong the efficacy of the drug, and improve the utilization rate of the medicinal bath.

[0032] Exemplarily, the particle size of the chitosan quaternary ammonium salt microspheres is 200nm-800nm.

[0033] Preferably, the plasticizer is glycerol.

[0034] The preferred plasticizer can improve the ductility of the film, enhance the mechanical strength of the film, and make the film more flexible.

[0035] Preferably, the surfactant is alkyl glycoside and sodium lauryl sulfate in a mass ratio of 1.2-2:1.

[0036] The preferred surfactant can improve the solubility of each component and enhance the permeability of the membrane, thereby facilitating full play of the role of each component.

[0037] Preferably, the thickener is at least one of carboxymethyl galactomannan or hydroxyethyl cellulose.

[0038] The preferred thickener can effectively control the slow release of the drug, and when combined with sodium alginate, it can improve the stability and viscosity of the film, while also making the formed film more resilient, thereby increasing the action time of the medicinal bath agent.

[0039] The present invention also provides a method for preparing a composition for treating cow mastitis, comprising the following steps:

[0040] Step 1, weighing each component according to the designed ratio, adding the weighed sodium chlorite effervescent tablet to 5wt%-10wt% distilled water, activating for 10min-15min, then adding 50wt%-75wt% distilled water, mixing evenly, to obtain a sodium chlorite solution;

[0041] Step 2: Evenly mix the weighed puerarin, chitosan-derived quaternary ammonium salt, modified nano zinc oxide, magnesium aluminum hydrotalcite, antibacterial agent, film-forming agent, plasticizer, surfactant and thickener with the sodium chlorite solution, and add the remaining distilled water to obtain a composition for treating cow mastitis.

[0042] The preparation method for treating cow mastitis provided by the invention has simple process, strong operability and is suitable for large-scale production and application.

[0043] The present invention also provides a medicine for treating cow mastitis, comprising the above-mentioned composition for treating cow mastitis.

[0044] Preferably, the dosage form of the medicine for treating cow mastitis is a medicinal bath.

[0045] The composition for treating cow mastitis provided by the present invention has excellent bactericidal ability, can form a thin film on the diseased skin, and the film has good adhesion to the diseased skin, can quickly repair and protect damaged or swollen parts. At the same time, it has low irritation to the skin, is safe and breathable, has good moisturizing effect, will not produce drug resistance, is conducive to improving the safety of cow dairy products, and has broad application prospects. DETAILED DESCRIPTION

[0046] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0047] Example 1

[0048] This embodiment provides a composite sodium chlorite effervescent tablet, comprising the following raw material components in parts by weight: 4.5 parts of sodium chlorite, 8.5 parts of tartaric acid, 1.0 part of sodium tetraborate, 1.0 part of sodium lauryl sulfate, 2.5 parts of sodium bicarbonate, 0.7 part of methylcellulose, 2.0 parts of polyethylene glycol, and 1.8 parts of a coating stabilizer;

[0049] Wherein, the coating stabilizer is a mixture of magnesium sulfate and nano-silicon dioxide in a mass ratio of 2.2:1.

[0050] The components are weighed according to the above designed ratio, mixed evenly, and tableted to obtain a composite sodium chlorite effervescent tablet.

[0051] The composite sodium chlorite effervescent tablets prepared using other raw material ratios specified in the present invention can achieve technical effects equivalent to those of the composite sodium chlorite effervescent tablets prepared above.

[0052] Example 2

[0053] This embodiment provides a method for preparing modified nano zinc oxide, comprising the following steps:

[0054] S1, crushing 10 g of rambutan peel, adding it to 550 mL of 95% ethanol solution, extracting it at 40°C for 1.5 h, separating the solid and liquid, repeating the extraction three times, and combining the extracts to obtain a rambutan extract;

[0055] S2. Mix 0.4 mol / L zinc nitrate solution and the rambutan extract in a volume ratio of 1:6, perform hydrothermal reaction at 65°C for 1 h, separate the solid and the liquid, and calcine the resulting solid at 500°C for 18 min to obtain modified zinc oxide nanoparticles.

[0056] The modified nano zinc oxide prepared by adopting other raw material ratios and reaction conditions specified in the present invention can achieve the same technical effects as the modified nano zinc oxide prepared above.

[0057] Example 3

[0058] This embodiment provides a method for preparing a polysaccharide-derived quaternary ammonium salt, comprising the following steps:

[0059] 2.5 g of chitosan was dissolved in 100 mL of 5% isopropanol solution, the pH was adjusted to 8, and then 25 mL of 75% 2,3-epoxypropyltrimethylammonium chloride aqueous solution was added. The mixture was reacted at 75° C. for 8 h and vacuum freeze-dried to obtain chitosan-derived quaternary ammonium salt.

[0060] The chitosan-derived quaternary ammonium salts prepared by adopting other raw material ratios and reaction conditions specified in the present invention can achieve the same technical effects as the chitosan-derived quaternary ammonium salt prepared above.

[0061] Example 4

[0062] This embodiment provides a method for preparing magnesium-aluminum hydrotalcite, comprising the following steps:

[0063] 0.25 mol / L aluminum nitrate solution and 0.75 mol / L magnesium nitrate solution were mixed uniformly in a volume ratio of 0.8:1. 50 mL of 0.35 mol / L sodium hydroxide solution and 100 mL of 0.5 mol / L sodium nitrate solution were added dropwise to 500 mL of the mixed solution at 70°C. The pH of the system was always controlled at 10.5-11.0 during the addition. After the addition was completed, the mixture was reacted for 5 h, centrifuged, washed, and dried to obtain magnesium-aluminum hydrotalcite.

[0064] The magnesium-aluminum hydrotalcites prepared by adopting other raw material ratios and reaction conditions specified in the present invention can achieve the same technical effects as the magnesium-aluminum hydrotalcite prepared above.

[0065] Example 5

[0066] This embodiment provides a medicinal bath for treating cow mastitis, comprising the following raw material components in parts by weight: 0.5 parts of the composite sodium chlorite effervescent tablet prepared in Example 1, 1.5 parts of puerarin, 2 parts of the chitosan-derived quaternary ammonium salt prepared in Example 3, 5 parts of the modified nano-zinc oxide prepared in Example 2, 2 parts of the magnesium-aluminum hydrotalcite prepared in Example 4, 3 parts of an antibacterial agent, 5 parts of a film-forming agent, 4 parts of glycerin, 3 parts of a surfactant, 1 part of hydroxyethyl cellulose, and 550 parts of distilled water.

[0067] Among them, the antibacterial agent is a mixture of gallnut extract, schisandra extract and coptis extract in a mass ratio of 1:1.2:0.5; the film-forming agent is a mixture of sodium alginate and chitosan quaternary ammonium salt microspheres in a mass ratio of 2.5:1; the surfactant is alkyl glycoside and sodium lauryl sulfate in a mass ratio of 2:1.

[0068] The preparation method of the above-mentioned medicinal bath agent for treating cow mastitis comprises the following steps:

[0069] Step 1: Weigh each component according to the designed ratio, add the weighed sodium chlorite effervescent tablet to 5wt% distilled water, activate for 10 minutes, then add 50wt% distilled water, mix well, and obtain a sodium chlorite solution;

[0070] Step 2: Evenly mix the weighed puerarin, chitosan-derived quaternary ammonium salt, modified nano zinc oxide, magnesium aluminum hydrotalcite, antibacterial agent, film-forming agent, plasticizer, surfactant and thickener with the sodium chlorite solution, and add the remaining distilled water to obtain a composition for treating cow mastitis.

[0071] Example 6

[0072] This embodiment provides a medicinal bath for treating cow mastitis, comprising the following raw material components in parts by weight: 2 parts of the composite sodium chlorite effervescent tablets prepared in Example 1, 1.2 parts of puerarin, 1.8 parts of the chitosan-derived quaternary ammonium salt prepared in Example 3, 1 part of the modified nano-zinc oxide prepared in Example 2, 6 parts of magnesium-aluminum hydrotalcite prepared in Example 4, 1.6 parts of an antibacterial agent, 10 parts of a film-forming agent, 2 parts of glycerin, 7 parts of a surfactant, 2 parts of hydroxyethyl cellulose, and 650 parts of distilled water.

[0073] Among them, the antibacterial agent is a mixture of gallnut extract, schisandra extract and coptis extract in a mass ratio of 1.2:1:0.8; the film-forming agent is a mixture of sodium alginate and chitosan quaternary ammonium salt microspheres in a mass ratio of 1.8:1; the surfactant is an alkyl glycoside and sodium lauryl sulfate in a mass ratio of 1.2:1.

[0074] The preparation method of the above-mentioned medicinal bath agent for treating cow mastitis comprises the following steps:

[0075] Step 1: Weigh each component according to the designed ratio, add the weighed sodium chlorite effervescent tablet to 10wt% distilled water, activate for 15 minutes, then add 75wt% distilled water, mix well, and obtain a sodium chlorite solution;

[0076] Step 2: Evenly mix the weighed puerarin, chitosan-derived quaternary ammonium salt, modified nano zinc oxide, magnesium aluminum hydrotalcite, antibacterial agent, film-forming agent, plasticizer, surfactant and thickener with the sodium chlorite solution, and add the remaining distilled water to obtain a composition for treating cow mastitis.

[0077] Example 7

[0078] This embodiment provides a medicinal bath for treating cow mastitis, comprising the following raw material components in parts by weight: 1 part of the composite sodium chlorite effervescent tablet prepared in Example 1, 1.3 parts of puerarin, 1.9 parts of the chitosan-derived quaternary ammonium salt prepared in Example 3, 3 parts of the modified nano-zinc oxide prepared in Example 2, 4 parts of magnesium-aluminum hydrotalcite prepared in Example 4, 2 parts of an antibacterial agent, 7 parts of a film-forming agent, 3 parts of glycerol, 5 parts of a surfactant, 1.5 parts of carboxymethyl galactomannan, and 600 parts of distilled water.

[0079] Among them, the antibacterial agent is a mixture of gallnut extract, schisandra extract and coptis extract in a mass ratio of 1.1:1.1:0.7; the film-forming agent is a mixture of sodium alginate and chitosan quaternary ammonium salt microspheres in a mass ratio of 2:1; the surfactant is alkyl glycoside and sodium lauryl sulfate in a mass ratio of 1.5:1.

[0080] The preparation method of the above-mentioned medicinal bath agent for treating cow mastitis comprises the following steps:

[0081] Step 1: Weigh each component according to the designed ratio, add the weighed sodium chlorite effervescent tablet to 8wt% distilled water, activate for 12 minutes, then add 60wt% distilled water, mix well, and obtain a sodium chlorite solution;

[0082] Step 2: Evenly mix the weighed puerarin, chitosan-derived quaternary ammonium salt, modified nano zinc oxide, magnesium aluminum hydrotalcite, antibacterial agent, film-forming agent, plasticizer, surfactant and thickener with the sodium chlorite solution, and add the remaining distilled water to obtain a composition for treating cow mastitis.

[0083] Comparative Example 1

[0084] This comparative example provides a medicinal bath for treating cow mastitis. The raw material composition and preparation method are exactly the same as those in Example 7. The only difference is that the modified nano zinc oxide in Example 7 is replaced by an equal amount of nano zinc oxide. The preparation method of nano zinc oxide is as follows:

[0085] A 0.4 mol / L zinc nitrate solution and a 95% ethanol solution were mixed uniformly in a volume ratio of 1:6, and hydrothermally reacted at 65°C for 1 hour. The solid-liquid separation was performed, and the resulting solid was calcined at 500°C for 18 minutes to obtain zinc oxide nanoparticles.

[0086] Comparative Example 2

[0087] This comparative example provides a medicinal bath agent for treating cow mastitis. The raw material composition and preparation method are exactly the same as those in Example 7, except that the chitosan-derived quaternary ammonium salt in Example 7 is replaced by an equal amount of chitosan.

[0088] Comparative Example 3

[0089] This comparative example provides a medicinal bath for treating cow mastitis. The raw material composition and preparation method are exactly the same as those in Example 7. The only difference is that the magnesium-aluminum hydrotalcite in Example 7 is replaced by an equal amount of magnesium hydrotalcite. The preparation method is as follows:

[0090] To 500 mL of 0.75 mol / L magnesium nitrate solution, 50 mL of 0.35 mol / L sodium hydroxide solution and 100 mL of 0.5 mol / L sodium nitrate solution were added dropwise. The pH of the system was always controlled at 10.5-11.0 during the addition. After the addition was completed, the mixture was reacted for 5 h, centrifuged, washed, and dried to obtain magnesium hydrotalcite.

[0091] Comparative Example 4

[0092] This comparative example provides a medicinal bath for treating cow mastitis. The raw material composition and preparation method are exactly the same as those in Example 7, except that the modified nano-zinc oxide in Example 7 is replaced by an equal amount of nano-titanium dioxide.

[0093] Comparative Example 5

[0094] This comparative example provides a medicinal bath for treating cow mastitis. The raw material composition and preparation method are exactly the same as those in Example 7, except that the chitosan-derived quaternary ammonium salt in Example 7 is replaced by an equal amount of modified nano zinc oxide.

[0095] Application Example 1 (Sterilization Test)

[0096] 1. Materials

[0097] 1.1 Bactericidal Agents: Cow Mastitis Baths Prepared in Examples 5-7 and Comparative Examples 1-5

[0098] 1.2 Bacteria: Escherichia coli (CMCC.44102), Staphylococcus aureus (CMCC.26003)

[0099] 1.3. Neutralizing agent: 1% sodium thiosulfate solution

[0100] 1.4 Diluent: 0.9% sodium chloride injection

[0101] 2. Test methods

[0102] Refer to the Technical Specifications for Identification of Veterinary Disinfectants (1992) Agricultural (Animal Medicine) No. 101.

[0103] The prepared bacterial solution was counted for viable bacteria and then diluted with sodium chloride injection to a concentration of 10 6 ~10 7 / mL of experimental bacterial solution. Prepare each test bactericidal agent sample with a test concentration of 1:600 ​​using sodium chloride injection. Pipette 0.5mL of the experimental bacterial solution into 4.5mL of the test concentration of bactericidal agent solution. 30s, 1min, and 5min after adding the bacterial solution, immediately draw 0.5mL of the above bacterial and drug mixture, add 4.5mL of neutralizing solution, neutralize for 10min, and then take out 0.1mL and spread it evenly in a culture dish with nutrient agar medium. Place the culture dish at 37℃ and culture for 24h, and count the number of colonies.

[0104] Another experiment was conducted with sodium chloride solution (0.9%) instead of bactericidal agent, and the above steps were carried out at the same time as the control group. Two parallel controls were set up for each of the above steps, and the test results are shown in Table 1.

[0105] Table 1

[0106]

[0107]

[0108] Application Example 2 (Skin Irritation Test)

[0109] Twenty-four dairy cows were divided into an intact skin group and a damaged skin group. The damaged skin group had the drug application site scratched in a "#" shape using a sterile surgical procedure, with bleeding being the limit. 24 hours before drug administration, both sides of the cow's back were depilated with 8% sodium sulfide, with each area 8 cm*8 cm on the left and right. The left side was the drug application area, and the right side was the control area. The drug application area was applied with the medicated bath prepared in Example 7, and the control area was applied with 0.9% normal saline without drug. The two areas were then covered with two layers of gauze and one layer of cellophane, and secured with a bandage. After 4 hours of application, the test drug was removed, and the drug application site was cleaned with warm water. One hour, 24 hours, 48 ​​hours, and 72 hours after the test drug was removed, the skin was observed under natural light for local reactions, including erythema and edema. The results are shown in Table 2.

[0110] Table 2

[0111]

[0112] Note: A reaction level of 0 indicates no stimulation, which is the standard for no or no detection of specific antibodies.

[0113] Application Example 3

[0114] 100 positive same-kind milk cows that are detected as recessive mastitis are test subjects.100 sick milk cows are divided into 10 groups at random, 10 in every group, use the medicated bath (embodiment group) of the embodiment of the present invention 7, use 0.5% chlorhexidine (control group 1), use 1% iodine tincture (control group 2), use 4% sodium hypochlorite solution (control group 3), use warm water (blank group), use the medicated bath (Comparative Example 1 group-Comparative Example 5 groups) prepared by Comparative Example 1-5.Each medicament uses and is to wipe udder with warm water before milking, soaks udder with each medicament after milking, and 90 days of trial period, tests the recessive mastitis detection respectively at the 0th day, 30 days, 60 days and 90 days.

[0115] Each teat area is considered a teat quarter. Drug efficacy is determined based on milk somatic cell counts combined with CMT test results, with criteria for cure, effectiveness, and ineffectiveness. The cure criterion is a negative latent mastitis test result, meaning a cow's latent mastitis test turns negative from positive. Effectiveness criterion is a positive latent mastitis test result, meaning a transition from latent mastitis to clinical mastitis. Ineffectiveness criterion is a positive latent mastitis test result but no clinical symptoms. During the trial period, cases of latent mastitis with obvious clinical symptoms were considered to have transitioned to clinical mastitis. The number of affected, cured, effective, and ineffective quarters was recorded, and the efficacy rate and cure rate were calculated. The results are shown in Table 3.

[0116] Effectiveness % = number of effective milk quarters * 100 / number of diseased milk quarters

[0117] Cure rate % = number of treated breast areas * 100 / number of affected breast areas.

[0118] Table 3

[0119]

[0120]

[0121] In the above embodiments, the gallnut extract, schisandra extract, and coptis chinensis extract are all aqueous extracts. The extraction method can be as follows: crush the gallnut, schisandra, or coptis chinensis, add the crushed raw materials to water at a material-liquid ratio of 1 g:20 mL, perform ultrasonic extraction at 50° C. for 1 hour, perform extraction three times, and combine the extracts to obtain the gallnut extract, schisandra extract, and coptis chinensis extract, respectively. Aqueous extracts prepared by other conventional methods in the art can also be used.

[0122] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A composition for treating cow mastitis, characterized in that: The invention comprises the following raw material components in parts by weight: 0.5-2 parts of composite sodium chlorite effervescent tablets, 1.2-1.5 parts of puerarin, 1.8-2.0 parts of chitosan-derived quaternary ammonium salt, 1-5 parts of modified nano zinc oxide, 2-6 parts of magnesium aluminum hydrotalcite, 1.6-3 parts of antibacterial agent, 5-10 parts of film-forming agent, 2-4 parts of plasticizer, 3-7 parts of surfactant, 1-2 parts of thickener and 550-650 parts of distilled water; The preparation method of the modified nano zinc oxide comprises the following steps: S1, crushing the rambutan peel, adding it to an ethanol solution, extracting it at 30°C-50°C for 1 hour-2 hours, separating the solid and the liquid, repeating the extraction 2-3 times, and combining the extracts to obtain a rambutan extract; S2, uniformly mixing the zinc nitrate solution and the rambutan extract, hydrothermally reacting at 60-70° C. for 1 h-1.5 h, separating the solid and the liquid, and calcining the obtained solid at 450-550° C. for 15-20 min to obtain modified zinc oxide nanoparticles.

2. The composition for treating cow mastitis according to claim 1, wherein The raw materials of the composite sodium chlorite effervescent tablet include the following raw material components in parts by weight: 3.6-5.0 parts of sodium chlorite, 8.2-8.6 parts of tartaric acid, 0.7-1.3 parts of sodium tetraborate, 0.7-1.3 parts of sodium lauryl sulfate, 2.4-2.7 parts of sodium bicarbonate, 0.6-0.9 parts of methylcellulose, 1.9-2.3 parts of polyethylene glycol, and 1.7-1.9 parts of a coating stabilizer.

3. The composition for treating cow mastitis according to claim 1, wherein The mass-to-volume ratio of the rambutan peel to the ethanol solution is 1:50-60, wherein the unit of mass is gram and the unit of volume is milliliter; and / or The mass concentration of the ethanol solution is 90%-95%; and / or The concentration of the zinc nitrate solution is 0.2 mol / L-0.5 mol / L, and the volume ratio of the zinc nitrate solution to the rambutan extract is 1:4-8.

4. The composition for treating cow mastitis according to claim 1, wherein The preparation method of the chitosan-derived quaternary ammonium salt comprises the following steps: Dissolve chitosan in isopropanol solution, adjust the pH to 8-9, then add 2,3-epoxypropyltrimethylammonium chloride aqueous solution, react at 60°C-90°C for 6h-10h, and dry to obtain chitosan-derived quaternary ammonium salt.

5. The composition for treating cow mastitis according to claim 4, wherein The mass concentration of the isopropanol solution is 5%-6%, and the volume-to-mass ratio of the isopropanol solution to the chitosan is 100:2.5-3, wherein the unit of volume is milliliter and the unit of mass is gram; and / or The mass concentration of the 2,3-epoxypropyltrimethylammonium chloride aqueous solution is 70%-80%, and the volume-to-mass ratio of the 2,3-epoxypropyltrimethylammonium chloride aqueous solution to chitosan is 20-25:2.5-3, wherein the unit of volume is milliliter and the unit of mass is gram.

6. The composition for treating cow mastitis according to claim 1, wherein The antibacterial agent is a mixture of Galla chinensis extract, Schisandra chinensis extract and Coptis chinensis extract in a mass ratio of 1-1.2:1.-1.2:0.5-0.8; and / or The film-forming agent is a mixture of sodium alginate and chitosan quaternary ammonium salt microspheres in a mass ratio of 1.8-2.5:1; and / or The plasticizer is glycerol; and / or The surfactant is an alkyl glycoside and sodium lauryl sulfate in a mass ratio of 1.2-2:1; and / or The thickener is at least one of carboxymethyl galactomannan and hydroxyethyl cellulose.

7. The method for preparing the composition for treating cow mastitis according to any one of claims 1 to 6, characterized in that: The following steps are involved: Step 1, weighing each component according to the designed ratio, adding the weighed sodium chlorite effervescent tablet to 5wt%-10wt% distilled water, activating for 10min-15min, then adding 50wt%-75wt% distilled water, mixing evenly, to obtain a sodium chlorite solution; Step 2: Evenly mix the weighed puerarin, chitosan-derived quaternary ammonium salt, modified nano zinc oxide, magnesium aluminum hydrotalcite, antibacterial agent, film-forming agent, plasticizer, surfactant and thickener with the sodium chlorite solution, and add the remaining distilled water to obtain a composition for treating cow mastitis.

8. A medicine for treating cow mastitis, characterized in that: The invention relates to a composition for treating cow mastitis comprising the composition according to any one of claims 1 to 6.

9. The medicine for treating cow mastitis according to claim 8, characterized in that Its dosage form is medicated bath.

Images